← back to search

Dan Zhao

The University of Texas MD Anderson Cancer Center · US
Area of research
Oncology · Pulmonary and Respiratory Medicine · breast cancer drug design
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Lung Cancer Treatments and Mutations, and Cancer Genomics and Diagnostics.
h-index
46
citations
7,070
works
390
NIH funding
primary concept
Medicine
email

Recent publications

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology 2025cited by 11position: middledoi
A Bayesian network for estimating hypertension risk due to occupational aluminum exposure
Chronic Diseases and Translational Medicine 2024cited by 4position: middledoi
Abstract CT076: AFNT-211: A phase1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
Cancer Research 2024cited by 3position: middledoi
The interaction between plasma polymetals and lifestyle on cognitive dysfunction in occupational aluminum exposed workers: A cross-sectional study in China
NeuroToxicology 2024cited by 2position: middledoi
Inflammatory factors predict infection risk during chemotherapy in leukemia patients
Microbial Pathogenesis 2024cited by 0position: middledoi
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
New England Journal of Medicine 2023cited by 690position: middledoi
International Consensus on Natural Orifice Specimen Extraction Surgery (NOSES) for Gastric Cancer (2019)
2023cited by 2position: middledoi
Forecasting and analysis of the effect of lifestyle on cognitive dysfunction induced by occupational aluminum exposure based on Bayesian networks
Environmental Toxicology and Pharmacology 2022cited by 6position: firstdoi
Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.
European journal of medicinal chemistry 2022cited by 0position: contributordoi
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
Leukemia 2021cited by 110position: middledoi
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).
Journal of Clinical Oncology 2020cited by 33position: middledoi
International consensus on natural orifice specimen extraction surgery (NOSES) for gastric cancer (2019)
Gastroenterology report 2019cited by 39position: middledoi
Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes
BMC Cancer 2019cited by 13position: middledoi
Angiotensin‐Converting Enzyme 3 (ACE3) Protects Against Pressure Overload‐Induced Cardiac Hypertrophy
Journal of the American Heart Association 2016cited by 13position: middledoi
Correlation between insulin-like growth factor binding protein 3 and metastasis-associated gene 1 protein in esophageal squamous cell carcinoma
Molecular Medicine Reports 2016cited by 7position: middledoi
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
Cancer Cell 2015cited by 444position: middledoi
Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i> -Mutant Gliomas
Clinical Cancer Research 2014cited by 194position: middledoi
Programming of the Development of Tumor-Promoting Neutrophils by Mesenchymal Stromal Cells
Cellular Physiology and Biochemistry 2014cited by 38position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Baolong Pan · Massachusetts Institute of Technology3 papers (2022–2024)Xiaoting Lu · Guangzhou University of Chinese Medicine3 papers (2022–2024)Jing Song · Shanxi Medical University3 papers (2022–2024)Jiaping Huan · Shanxi Medical University3 papers (2022–2024)Linping Wang · Kunming University of Science and Technology3 papers (2022–2024)Huifang Zhang · Nanjing Tech University3 papers (2022–2024)Q. L. Niu · Southeast University3 papers (2022–2024)Nikolay Tzvetkov · Ningbo University2 papers (2020–2021)Dominik Selleslag · AZ Sint-Jan2 papers (2020–2021) · 2 papers (2020–2021)Joshua F. Zeidner · University of North Carolina at Chapel Hill2 papers (2020–2021) · 2 papers (2020–2021)Mikkael A. Sekeres · Yale University2 papers (2020–2021)María Díez‐Campelo · Universidad de Salamanca2 papers (2020–2021)Atanas Radinoff · University of Arkansas for Medical Sciences2 papers (2020–2021) · 2 papers (2024–2024)Jane L. Liesveld · University of Rochester Medical Center2 papers (2020–2021)Douglas V. Faller · Boston University2 papers (2020–2021)Patricia Font · Hospital Universitario Fundación Jiménez Díaz2 papers (2020–2021)Tianshu Wang · Nanjing University of Chinese Medicine2 papers (2022–2024)